Formulation of risperidone loaded proniosomes for effective transdermal delivery: An in-vitro and in-vivo study

Sambhakar, Sharda; Paliwal, Sarvesh; Sharma, Swapnil; Singh, Bishambar

doi:10.1016/j.bfopcu.2017.09.003

Cited by 42 publications

(47 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was obvious that using a high HLB surfactant (Kolliphor RH40), resulted in the formation of smaller vesicles compared to the low HLB surfactant (Brij 93). These findings were in accordance with Sambhakar et al [29], where smaller vesicles were obtained upon using tweens rather than spans, which is due to the larger head groups and decreasing length of alkyl chains in the structure of high HLB surfactants [55]. On the other hand, increasing the surfactant concentration led to an increase in the vesicle size.…”

Section: Discussionsupporting

confidence: 92%

“…Nonionic surfactants are commonly used in proniosomes due to their stability, wide compatibility and low toxicity [27] whereas, lecithin acts as a permeation enhancer, besides its role in the reduction of vesicular size and limiting drug leakage [28]. Cholesterol is incorporated to increase the stability of the vesicular membrane, whereas added alcohol increases the skin permeability [29]. Finally, the water addition leads to swelling of bilayer, producing spherical multilamellar vesicles [28].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fabrication of Anti-HSV-1 Curcumin Stabilized Nanostructured Proniosomal Gel: Molecular Docking Studies on Thymidine Kinase Proteins

et al. 2020

View full text Add to dashboard Cite

Curcumin is a dietary compound with accrued evidence of antiviral activity. Poor solubility and permeation renders curcumin a good applicant for incorporation into proniosomes. The intent of this study was to formulate curcumin proniosomal gel for topical application and the evaluation of its in-vitro, ex-vivo activities against Herpes Simplex virus type 1 (HSV-1), as well as molecular docking studies on HSV-1 thymidine kinase proteins. Coacervation phase separation tactic, using 23 full factorial design, was used in the preparation of different proniosomes. Cytotoxicity of the selected formulae (F4 and F8) was evaluated on the Vero cell line. Optimal formulae (F4 and F8) showed entrapment efficiency of 97.15 ± 2.47% and 95.85 ± 2.9%, vesicle size of 173.7 ± 2.26 nm and 206.15 ± 4.17 nm and percentages curcumin released after 3 h of 51.9 ± 1.4% and 50.5 ± 1.1%, respectively. Ex-vivo permeation studies demonstrated that the optimal formulae markedly improved the dermal curcumin delivery. Curcumin proniosomal gel formulae exhibited 85.4% reduction of HSV-1 replication. The ability of curcumin to interact with the key amino acids in the enzyme binding sites of 1KI7, 1KI4, and 1E2P, as indicated by its docking pattern, rationalized its observed activity. Therefore, curcumin proniosomes could be considered as a successful topical delivery system for the treatment of HSV-1.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Fabrication of Anti-HSV-1 Curcumin Stabilized Nanostructured Proniosomal Gel: Molecular Docking Studies on Thymidine Kinase Proteins

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Gelatin 2%w/v was used to get the optimised transdermal patch formulation were gelatin is used for its excellent natural film-forming properties [68][69]. The prepared niosomes were loaded into the patch formulation to which turpentine oil was added as a natural permeation enhancer [70]. The formulations of niosomal transdermal patches are shown in table 1(A) and table 1(B).…”

Section: Formulation Of Midazolam Loaded Niosomal Transdermal Patchmentioning

confidence: 99%

Anti-Epileptic Drug Loaded Niosomal Transdermal Patch for Enhanced Skin Permeation

et al. 2019

View full text Add to dashboard Cite

Objective: To formulate and characterize midazolam loaded niosomal transdermal patches for overcoming the frequent dosing and lower bioavailability complications associated with conventional therapy. Methods:The loaded niosomal transdermal patches were prepared by thin film hydration method. The preliminary evaluation and characterization studies was conducted to find the optimised formulation. The in vitro release and ex-vivo permeation studies were investigated. The histopathological studies and stability studies were also assessed. Results:The midazolam loaded niosomal transdermal patches of vesicle size and zeta potential 116.1±84.46 d. nm and 8.56±1.2 mV respectively was formulated. The characterizations of both niosome and niosomal transdermal patches were found to be within the acceptable limits. The in vitro drug release showed an initial burst release followed by sustained release for both optimised niosomal formulation N5 and optimised niosomal transdermal patch formulation NT5with a maximum activity at 97.3±0.35% and 98.9±0.20% respectively. The ex vivo permeation studies of niosomal transdermal patch NT5 was performed which showed a higher permeability than control solution with a flux value of 0.151. The histopathological studies of the optimised formulation showed no detectable lesions upon skin surface and irritations. The stability studies showed that patches were stable over 90 d in different atmospheric conditions. Conclusion:The midazolam loaded niosomal transdermal patch was found to be a promising nano drug delivery alternative which showed better entrapment, release with permeation profile for the daily management of epilepsy with decreased dosing frequency. I In nt te er rn na at ti io on na al l J Jo ou ur rn na al l o of f A Ap pp pl li ie ed d P Ph ha ar rm ma ac ce eu ut ti ic cs s

show abstract

“…Ex vivo skin permeation studies were performed using same procedure and analytical method as used for in vitrorelease studies. The cellophane membrane was replaced with subcutaneous skin of male albino Wistar rats with diffusion area of 2.26 cm 2 .The skin was properly cleaned to remove the subcutaneous fat and other blood vessels.The cumulative amount of drug permeated across the rat skin was calculated and plotted against time and the flux was calculated as drug permeated per cm 2 per hour 30 .…”

Section: Determination Of Drug Contentmentioning

confidence: 99%

“…found to be 71.28±1.66 % after 6 h. Span 20 has a relatively lower phase transition temperature (16) and the proniosomes get converted to niosomes due to hydration by skin moisture at skin temperature. This also makes the vesicle bilayers more fluid and leaky resulting in release of the drug 30 . Rahman et al 32 stated that niosomes exhibit an alkyl chain length-dependent release and the higher the chain length, the lower the release rate.…”

Section: In Vitro Release Studies and Ex Vivo Permeation Studiesmentioning

confidence: 99%

Formulation and Evaluation of Topical Formulation for Cutaneous Tuberculosis

Rao¹,

Kadam²,

Rao³

2018

J. Drug Delivery Ther.

View full text Add to dashboard Cite

Cutaneous Tuberculosis is also known as dermal tuberculosis or tuberculosis cutis (extrapulmonary tuberculosis) which can occur in any age group and patients who may or may not be suffering from pulmonary tuberculosis. The current treatment given for the disease is oral therapy of anti-tubercular drugs which has many side effects such as hepatotoxicity, headache, anxiety, euphoria, insomnia, eosinophilia, hepatitis. Hence to avoid these side effects and to increase efficiency of current therapy a topical proniosomal gel of isoniazid was formulated. Coacervation phase separation method was used and proniosomal gel was formulated by using Span 20, soya lecithin, and cholesterol. Optimum concentration of 3 factors Span 20, soya lecithin, and cholesterol were determined using Box Behnken design with at 2 levels and vesicle size and entrapment efficiency as responses. The optimized proniosomal gel was characterized by vesicle size, entrapment efficiency, transmission electron microscopy (TEM), in vitro drug release, skin retention studies, skin irritation studies and stability studies. The optimised batch showed vesicle size of 2.27±1.82 µ, and entrapment efficiency of 98.15±0.25 %. The optimised formulation was stable under refrigeration condition (5°C) in amber coloured bottle, was non-irritating and showed 98.10±1.28 % release and 85±1.53 % permeation after 6 h and 436±12 µg drug was retained in the skin after 3 hrs.

show abstract

Formulation of risperidone loaded proniosomes for effective transdermal delivery: An in-vitro and in-vivo study

Cited by 42 publications

References 33 publications

Fabrication of Anti-HSV-1 Curcumin Stabilized Nanostructured Proniosomal Gel: Molecular Docking Studies on Thymidine Kinase Proteins

Fabrication of Anti-HSV-1 Curcumin Stabilized Nanostructured Proniosomal Gel: Molecular Docking Studies on Thymidine Kinase Proteins

Anti-Epileptic Drug Loaded Niosomal Transdermal Patch for Enhanced Skin Permeation

Formulation and Evaluation of Topical Formulation for Cutaneous Tuberculosis

Contact Info

Product

Resources

About